{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:26:58Z","timestamp":1758475618851},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1694,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1111\/j.1472-8206.2010.00908.x","type":"journal-article","created":{"date-parts":[[2011,1,11]],"date-time":"2011-01-11T10:57:47Z","timestamp":1294743467000},"page":"753-761","source":"Crossref","is-referenced-by-count":18,"title":["Use of intravenous immunoglobulins in clinical practice: data from three French university hospitals"],"prefix":"10.1111","volume":"25","author":[{"given":"Elisabeth","family":"Frauger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Pradel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charleric","family":"Bornet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Rouby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Delorme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastien","family":"Ousset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Braguer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Philippe","family":"Azulay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Penot-Ragon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Robert","family":"Harle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Claude","family":"Bongrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Jean","family":"Weiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Pouget","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Michel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joelle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Reynier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Tardieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Vanelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Blin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Immunoglobulin Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,1,11]]},"reference":[{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1445-5994.2007.01336.x","article-title":"How intravenous immunoglobulin is used in clinical practice: audits of two Sydney teaching hospitals","volume":"37","author":"Lin","year":"2007","journal-title":"Intern. Med. J."},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2005.02834.x","article-title":"Clinical uses of intravenous immunoglobulin","volume":"142","author":"Jolles","year":"2005","journal-title":"Clin. Exp. Immunol."},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"356","DOI":"10.7861\/clinmedicine.6-4-356","article-title":"Current clinical uses of intravenous immunoglobulin","volume":"6","author":"El-Shanawany","year":"2006","journal-title":"Clin. Med."},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1196\/annals.1423.054","article-title":"Intravenous immunoglobulin and autoimmune disease","volume":"1110","author":"El-Shanawany","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.molimm.2004.07.046","article-title":"Therapeutic intravenous immunoglobulins","volume":"42","author":"Lemieux","year":"2005","journal-title":"Mol. Immunol."},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1111\/j.1537-2995.2007.01400.x","article-title":"Intravenous immunoglobulin utilization in the Canadian Atlantic provinces: a report of the Atlantic Collaborative Intravenous Immune Globulin Utilization Working Group","volume":"47","author":"Constantine","year":"2007","journal-title":"Transfusion"},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1537-2995.2006.00792.x","article-title":"Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature","volume":"46","author":"Darabi","year":"2006","journal-title":"Transfusion"},{"issue":"2 Suppl 1","key":"10.1111\/j.1472-8206.2010.00908.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.tmrv.2007.01.004","article-title":"Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions","volume":"21","author":"Robinson","year":"2007","journal-title":"Transfus. Med. Rev."},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2146\/ajhp070582","article-title":"Unlabeled uses of intravenous immune globulin","volume":"65","author":"Leong","year":"2008","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1423-0410.2005.00670.x","article-title":"Changes in intravenous immunoglobulin prescribing patterns during a period of severe product shortages, 1995-2000","volume":"89","author":"Pendergrast","year":"2005","journal-title":"Vox Sang."},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1345\/aph.19252","article-title":"A multicenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centers","volume":"34","author":"Chen","year":"2000","journal-title":"Ann. Pharmacother."},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.beha.2005.01.032","article-title":"Use of intravenous immunoglobulin G (IVIG)","volume":"19","author":"Looney","year":"2006","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB13|cit13","unstructured":"Clinical guidelines for the use of intravenous immunoglobulin 2008 http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_085235"},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB14|cit14","unstructured":"Criteria for the clinical use of intravenous immunoglobulin in Australia 2007 http:\/\/www.nba.gov.au\/IVIg\/pdf\/criteria.pdf"},{"issue":"2 Suppl 1","key":"10.1111\/j.1472-8206.2010.00908.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.tmrv.2007.01.003","article-title":"Guidelines for the use of intravenous immune globulin for hematologic and neurologic conditions","volume":"21","author":"Hume","year":"2007","journal-title":"Transfus. Med. Rev."},{"issue":"2 Suppl 1","key":"10.1111\/j.1472-8206.2010.00908.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.tmrv.2007.01.002","article-title":"Guidelines on the use of intravenous immune globulin for neurologic conditions","volume":"21","author":"Feasby","year":"2007","journal-title":"Transfus. Med. Rev."},{"issue":"2 Suppl 1","key":"10.1111\/j.1472-8206.2010.00908.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.tmrv.2007.01.001","article-title":"Guidelines on the use of intravenous immune globulin for hematologic conditions","volume":"21","author":"Anderson","year":"2007","journal-title":"Transfus. Med. Rev."},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1684\/ejd.2008.0580","article-title":"Guidelines on the use of high-dose intravenous immunoglobulin in dermatology","volume":"19","author":"Enk","year":"2009","journal-title":"Eur. J. Dermatol."},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB19|cit19","first-page":"11","article-title":"Intravenous immune globulin use in Canada","volume":"10","author":"Hanna","year":"2003","journal-title":"Can. J. Clin. Pharmacol."},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB20|cit20","unstructured":"EMA Guideline on the clinical investigation of human normal. Immunoglobulin for intravenous administration (IVIg) 2009 http:\/\/www.emea.europa.eu\/pdfs\/human\/bpwg\/038895endraft.pdf"},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB21|cit21","unstructured":"Afssaps Summary of Product Characteristics of Tegeline \u00ae http:\/\/afssaps-prd.afssaps.fr\/php\/ecodex\/frames.php?specid=69174658&typedoc=R&ref=R0166798.htm"},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB22|cit22","unstructured":"French Health Products Agency (AFSSAPS) Guidelines for good use of immunoglobulin http:\/\/www.afssaps.fr\/Dossiers-thematiques\/Tarification-a-l-activite-T2A-medicaments\/Immunoglobulines2\/(offset)\/8"},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB23|cit23","unstructured":"French Health Products Agency (AFSSAPS) Unlabelled indications for which the benefit-risk can not be assessed due to lack of current scientific evidence http:\/\/www.afssaps.fr\/var\/afssaps_site\/storage\/original\/application\/0774a9c84d6f18126cd5481cbc3fb65f.pdf"},{"issue":"Suppl 1","key":"10.1111\/j.1472-8206.2010.00908.x-BIB24|cit24","first-page":"1S5","article-title":"Evolution of polyvalent intravenous immunoglobulins (IVIg) prescription, at the Assistance Publique - Hopitaux de Paris between 1988 and 1997. Results of the plan of action set up in order to regulate the prescription","volume":"151","author":"Courtay","year":"2000","journal-title":"Ann. Med. Interne (Paris)"},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB25|cit25","unstructured":"Presentation of the CEDIT http:\/\/cedit.aphp.fr\/english\/index_present.html"},{"issue":"1","key":"10.1111\/j.1472-8206.2010.00908.x-BIB26|cit26","first-page":"1","article-title":"Indications for immunoglobulins. Recommendations of CEDIT of AP-HP in 2006","volume":"28","author":"Guillevin","year":"2007","journal-title":"Rev. Med. Interne"},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/pds.1328","article-title":"Use of albumin in three French university hospitals: is prescription monitoring still useful in 2004?","volume":"16","author":"Pradel","year":"2007","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1111\/j.1472-8206.2010.00908.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ncpneuro1046","article-title":"Intravenous immunoglobulin for neuromuscular disease: costs, benefits and reimbursement","volume":"5","author":"Griffin","year":"2009","journal-title":"Nat. Clin. Pract. Neurol."}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1472-8206.2010.00908.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1472-8206.2010.00908.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T06:05:25Z","timestamp":1625551525000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1472-8206.2010.00908.x"}},"subtitle":["Use of intravenous immunoglobulins in France"],"short-title":[],"issued":{"date-parts":[[2011,1,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1472-8206.2010.00908.x","relation":{},"ISSN":["0767-3981"],"issn-type":[{"type":"print","value":"0767-3981"}],"subject":[],"published":{"date-parts":[[2011,1,11]]}}}